Education
About Us
Working with TipRanks
Follow Us
Ars Pharmaceuticals, Inc. (SPRY)
NASDAQ:SPRY
SPRY Stock Chart & Stats
$8.89
-$0.02(-0.18%)
At close: 4:00 PM EST
$8.89
-$0.02(-0.18%)
Day’s Range― - ―
52-Week Range$6.66 - $18.90
Previous CloseN/A
Volume456.05K
Average Volume (3M)1.10M
Market Cap
$811.26M
Enterprise Value$863.24M
Total Cash (Recent Filing)$244.99M
Total Debt (Recent Filing)$96.96M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
May 19, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding99,297,310
10 Day Avg. Volume1,489,352
30 Day Avg. Volume1,104,202
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)10.05
Price to Sales (P/S)13.63
P/FCF Ratio-6.71
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue10.24
Enterprise Value/Gross Profit13.52
Enterprise Value/Ebitda-5.04
Forecast
1Y Price Target
$19.53Price Target Upside119.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.38
Revenue Forecast (FY)$172.78M
Bulls Say, Bears Say
Bulls Say
International Regulatory ProgressAnalyst points out approval in China provides market access to a large patient population and supports partner milestone and royalty opportunities that could bolster commercial growth.
Revenue And Commercial TractionAnalyst notes reported revenue exceeded expectations, signaling stronger-than-anticipated commercial traction and growing physician adoption of the product.
Salesforce Expansion And MarketingAnalyst highlights plans to expand the salesforce by reallocating resources and to combine direct-to-consumer advertising with virtual prescribing and a patient assistance program, which should increase prescriber engagement and broaden patient awareness.
Bears Say
Regulatory UncertaintyAnalyst highlights that the regulator did not specify the deficiencies, leaving unclear what additional studies or labeling changes might be required and creating uncertainty around regulatory timelines.
Seasonality And Commercial HeadwindsAnalyst notes the company faced headwinds that limited its ability to fully capitalize on seasonal demand peaks, which may pressure near-term sales momentum.
ARS Pharmaceuticals News
SPRY FAQ
What was Ars Pharmaceuticals, Inc.’s price range in the past 12 months?
Ars Pharmaceuticals, Inc. lowest stock price was $6.66 and its highest was $18.90 in the past 12 months.
What is Ars Pharmaceuticals, Inc.’s market cap?
Ars Pharmaceuticals, Inc.’s market cap is $811.26M.
When is Ars Pharmaceuticals, Inc.’s upcoming earnings report date?
Ars Pharmaceuticals, Inc.’s upcoming earnings report date is May 19, 2026 which is in 57 days.
How were Ars Pharmaceuticals, Inc.’s earnings last quarter?
Ars Pharmaceuticals, Inc. released its earnings results on Mar 09, 2026. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.43 by $0.02.
Is Ars Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Ars Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Ars Pharmaceuticals, Inc. pay dividends?
Ars Pharmaceuticals, Inc. does not currently pay dividends.
What is Ars Pharmaceuticals, Inc.’s EPS estimate?
Ars Pharmaceuticals, Inc.’s EPS estimate is -0.49.
How many shares outstanding does Ars Pharmaceuticals, Inc. have?
Ars Pharmaceuticals, Inc. has 99,297,310 shares outstanding.
What happened to Ars Pharmaceuticals, Inc.’s price movement after its last earnings report?
Ars Pharmaceuticals, Inc. reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.43. Following the earnings report the stock price went down -0.11%.
Which hedge fund is a major shareholder of Ars Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SPRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ARS Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.53 (119.69% Upside)
$19.53 (119.69% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 47.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.90%
12-Months-Change
Fundamentals
Return on Equity
-100.29%
Trailing 12-Months
Asset Growth
-6.69%
Trailing 12-Months
Company Description
Ars Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
SPRY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant revenue growth and strategic initiatives like the 'Get Nephi On Us' program and global expansion. However, challenges such as temporary pauses in market share growth, data inaccuracies, and expected Q4 sales decline were noted.View all SPRY earnings summariesSPRY Stock 12 Month Forecast
Average Price Target
$19.53
▲(119.69% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Pharming Group
―
Maze Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---